Insider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $15,475.00 in Stock

Key Points

• Zai Lab CFO Yajing Chen sold 619 shares at $25 each for total proceeds of $15,475, reducing her stake by 1.73% to 35,072 shares. She also sold 2,264 shares in June for approximately $39,529.
• ZLAB shares recently traded at $26.03, up $0.54, with a market capitalization of about $2.96 billion. The stock remains unprofitable, reporting a quarterly loss of $0.50 per share and negative net margins.
• Analyst sentiment is mixed but leans positive: Zai Lab has a consensus “Moderate Buy” rating and an average price target of $40.20, compared with its recent trading price.

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CFO Yajing Chen sold 619 shares of the company's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $25.00, for a total transaction of $15,475.00. Following the transaction, the chief financial officer owned 35,072 shares in the company, valued at $876,800. This represents a 1.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Yajing Chen also recently made the following trade(s):

• On Friday, June 26th, Yajing Chen sold 2,264 shares of Zai Lab stock. The shares were sold at an average price of $17.46, for a total transaction of $39,529.44.

Zai Lab Stock Performance

Shares of ZLAB stock traded up $0.54 during trading hours on Thursday, reaching $26.03. The company had a trading volume of 1,041,801 shares, compared to its average volume of 843,216. The business has a fifty day moving average price of $19.22 and a 200-day moving average price of $19.39. Zai Lab Limited Unsponsored ADR has a one year low of $15.96 and a one year high of $36.77. The firm has a market cap of $2.96 billion, a PE ratio of -15.22 and a beta of 0.78.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported ($0.50) earnings per share for the quarter. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. The company had revenue of $106.31 million for the quarter. Equities research analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.17 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ZLAB shares. Zacks Research raised Zai Lab from a "strong sell" rating to a "hold" rating in a report on Tuesday, July 7th. Citigroup lifted their price objective on Zai Lab from $44.00 to $45.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Weiss Ratings upgraded Zai Lab from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen downgraded Zai Lab from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $40.20.

Institutional Trading of Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC grew its holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) by 6.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,396 shares of the company's stock after acquiring an additional 642 shares during the period. SG Americas Securities LLC's holdings in Zai Lab were worth $183,000 as of its most recent SEC filing. 41.65% of the stock is owned by institutional investors and hedge funds.

Zai Lab Company Profile

Zai Lab Ltd NASDAQ: ZLAB is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company's end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company's marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton's tyrosine kinase inhibitor approved for several B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source